№ files_lp_4_process_2_54992
File format: docx Character count: 32696 File size: 483 KB
The study evaluates the effect of taking Abiraterone with food on progression-free survival and toxicity in metastatic castration-resistant prostate cancer patients, comparing fasted versus fed intake conditions.
Year: 2022
Region / city: Netherlands
Topic: Cancer treatment, Abiraterone, Prostate cancer
Document type: Research study
Institution: Ziekenhuis Gelderse Vallei, Radboudumc
Author: Indy Murdoch, Emmy Boerrigter, Arnold Baars, Floor Lubberman
Target audience: Healthcare professionals, Researchers
Period of validity: N/A
Date of approval: February 4, 2022
Date of changes: N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Supplemental MaterialThe PSMA-Targeting Half-Life Extended BiTE® Therapy AMG 160 Has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Year: 2026
Region / city: South San Francisco, CA, USA; Munich, Germany
Subject: Oncology, Cancer Research
Document type: Research Paper
Organization: Amgen Research
Author: Petra Deegen, Oliver Thomas, Olivier Nolan-Stevaux, Shyun Li, Joachim Wahl, Pamela Bogner, Famke Aeffner, Matthias Friedrich, Michael Z. Liao, Katja Matthes, Doris Rau, Benno Rattel, Tobias Raum, Peter Kufer, Angela Coxon, Julie M. Bailis
Target audience: Researchers, oncologists, biotechnologists
Period of validity: Not specified
Approval date: Not provided
Date of changes: Not provided
Topics: life-Expectancy AFRODITE mCRPC